DANA-FARBER CANCER INSTITUTE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1947-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.dana-farber.org/
Psychedelic Therapy Expands Beyond Cancer Care as Multi-Center Studies Launch
Sunstone Therapies has conducted over 150 MDMA sessions through expanded access programs, demonstrating the drug's relational properties that facilitate therapeutic conversations and empathy.
First-in-Class CBP/p300 Inhibitor TT125-802 Shows Promise in Treatment-Resistant NSCLC
TT125-802, a novel oral CBP/p300 bromodomain inhibitor, demonstrated early clinical activity in advanced solid tumors with a favorable safety profile in an ongoing phase 1 trial.
Dr. Elizabeth Mittendorf Outlines Vision as ASCO President-Elect to Advance Multidisciplinary Cancer Care and Workforce Support
Dr. Elizabeth Mittendorf, the 2026-2027 ASCO President-Elect, will focus on advancing multidisciplinary collaboration, broadening clinical trial access, and strengthening oncology workforce support during her presidency.
Leon-nanodrugs Appoints Dr. Wolfgang Hofmann as CEO to Drive Nanoparticle Manufacturing Technology Commercialization
Munich-based leon-nanodrugs GmbH has appointed Dr. Wolfgang Hofmann as CEO to lead the company's transition from development to commercialization of its FR-JET® nanoparticle manufacturing technology.
AMPLITUDE Trial Shows Niraparib Combination Reduces Cancer Progression Risk by 37% in HRR-Mutant Metastatic Prostate Cancer
The phase III AMPLITUDE trial demonstrated that adding niraparib to abiraterone acetate plus prednisone significantly improved radiographic progression-free survival in patients with metastatic castration-sensitive prostate cancer harboring HRR gene alterations.
Trastuzumab Deruxtecan Combination Reduces Disease Progression Risk by 44% in HER2-Positive Metastatic Breast Cancer
A new treatment combining trastuzumab deruxtecan (T-DXd) with pertuzumab reduced the risk of disease progression or death by 44% compared to standard care in HER2-positive metastatic breast cancer patients.
RLY-2608 Shows Promise in PIK3CA-Mutant Breast Cancer with Improved Tolerability Profile
RLY-2608, a mutant-selective PI3Kα inhibitor, combined with fulvestrant achieved a 38.7% overall response rate and 10.3-month median progression-free survival in patients with PIK3CA-mutant HR+/HER2- advanced breast cancer.
DLL3-Targeted CAR-T Therapy LB2102 Shows Promise in Relapsed/Refractory Small Cell Lung Cancer
LB2102, a DLL3-directed autologous CAR-T cell therapy, demonstrated preliminary antitumor activity with a 16.7% objective response rate and 66.7% disease control rate in patients with relapsed/refractory small cell lung cancer and large cell neuroendocrine carcinoma.
Anti-Inflammatory Diet Reduces Death Risk by 87% in Stage III Colon Cancer Patients
Patients with stage III colon cancer consuming the most pro-inflammatory diets had an 87% higher risk of death compared to those with the least inflammatory diets in a phase 3 clinical trial analysis.
Casdatifan Plus Cabozantinib Combination Shows 46% Response Rate in Kidney Cancer Trial
Arcus Biosciences reported a 46% confirmed overall response rate for the casdatifan plus cabozantinib combination in patients with clear cell renal cell carcinoma who had progressed on prior immunotherapy.